{
    "eid": "2-s2.0-85086860265",
    "title": "Pharmacokinetics of nucleoside/nucleotide reverse transcriptase inhibitors for the treatment and prevention of HIV infection",
    "cover-date": "2020-07-02",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Toxicology",
            "@code": "3005",
            "@abbrev": "PHAR"
        },
        {
            "@_fa": "true",
            "$": "Pharmacology",
            "@code": "3004",
            "@abbrev": "PHAR"
        }
    ],
    "keywords": [
        "HIV",
        "nucleoside reverse transcriptase inhibitors",
        "nucleotide reverse transcriptase inhibitor",
        "pharmacokinetics"
    ],
    "authors": [
        "Piyanuch Wonganan",
        "Wacharee Limpanasithikul",
        "Suree Jianmongkol",
        "Stephen J. Kerr",
        "Kiat Ruxrungtham"
    ],
    "citedby-count": 4,
    "ref-count": 116,
    "ref-list": [
        "Survival in HIV-infected patients who have received zidovudine: comparison of combination therapy with sequential monotherapy and continued zidovudine monotherapy. Multicenter AIDS cohort study group",
        "Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group",
        "Addressing the selectivity and toxicity of antiviral nucleosides",
        "Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase",
        "Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors",
        "Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed therapy",
        "Abacavir: a review of its clinical potential in patients with HIV infection",
        "Pharmacokinetics and bioavailability of zidovudine in humans",
        "Plasma and cerebrospinal fluid pharmacokinetics of 3\u02b9-azido-3\u02b9-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases",
        "Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast",
        "CSF penetration by antiretroviral drugs",
        "Clinical pharmacokinetics of zidovudine. An overview of current data",
        "Comparative pharmacokinetics of antiviral nucleoside analogues",
        "New drug interactions with zidovudine",
        "Glucuronidation of 3\u02b9-azido-3\u02b9-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid",
        "Atovaquone inhibits the glucuronidation and increases the plasma concentrations of zidovudine",
        "Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients",
        "Methadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)",
        "Pharmacokinetic interaction between zidovudine and valproic acid in patients infected with human immunodeficiency virus",
        "Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection",
        "Clinical pharmacokinetics of lamivudine",
        "The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study",
        "Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine",
        "Pharmacokinetics of 3TC (GRI09714X) administered with and without food to HIV-infected patient",
        "A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection",
        "Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction",
        "Intracellular pharmacokinetics of antiretroviral drugs in HIV-infected patients, and their correlation with drug action",
        "Lamivudine for the treatment of HIV",
        "Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity",
        "Peripheral neuropathy and antiretroviral drugs",
        "Emtricitabine: an antiretroviral agent for HIV infection",
        "Emtricitabine: a once-daily nucleoside reverse transcriptase inhibitor",
        "Emtricitabine: a new nucleoside analogue for once-daily antiretroviral therapy",
        "Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food",
        "Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study",
        "A review of the pharmacokinetics of abacavir",
        "Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid",
        "Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function",
        "Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens",
        "Steady-state pharmacokinetics of abacavir in plasma and intracellular carbovir triphosphate following administration of abacavir at 600 milligrams once daily and 300 milligrams twice daily in human immunodeficiency virus-infected subjects",
        "Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection",
        "Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection",
        "Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics",
        "Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus",
        "Tenofovir alafenamide",
        "The phase 3 discover study: daily F/TAF or F/TDF for HIV preexposure prophylaxis",
        "FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic",
        "Tenofovir alafenamide versus tenofovir disoprozil fumarate: systematic review and meta-analysis",
        "Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide: a review in HIV-1 infection",
        "Is tenofovir alafenamide safer than tenofovir disoproxil fumarate for the kidneys?",
        "Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment",
        "Tenofovir alafenamide for the treatment of chronic hepatitis B monoinfection",
        "Pharmacokinetics of tenofovir alafenamide when coadministered with other HIV antiretrovirals",
        "Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide",
        "Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients",
        "Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial",
        "Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: a pooled analysis of 26 clinical trials",
        "Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?",
        "Pharmacologic-based methods of adherence assessment in HIV prevention",
        "Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission",
        "HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention",
        "Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis",
        "Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis",
        "Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial",
        "Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP)",
        "Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring",
        "Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure",
        "Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men",
        "Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men",
        "Levels of intracellular phosphorylated tenofovir and emtricitabine correlate with natural substrate concentrations in peripheral blood mononuclear cells of persons prescribed daily oral truvada for HIV pre-exposure prophylaxis",
        "4\u02b9-Ethynyl-2-fluoro-2\u02b9-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms",
        "Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1",
        "First-in-human trial of MK-8591-eluting implants demonstrates concentrations suitable for HIV prophylaxis for at least one year",
        "The pharmacology of antiretroviral nucleoside and nucleotide reverse transcriptase inhibitors: implications for once-daily dosing",
        "The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters",
        "MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs",
        "The role of breast cancer resistance protein (BCRP/ABCG2) in cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors",
        "Abcg2/Bcrp1 mediates the polarized transport of antiretroviral nucleosides abacavir and zidovudine",
        "Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults",
        "Decrease in thymidylate kinase activity in peripheral blood mononuclear cells from HIV-infected individuals",
        "Intracellular interactions between nucleos(t)ide inhibitors of HIV reverse transcriptase",
        "In vivo antagonism with zidovudine plus stavudine combination therapy",
        "Cellular pharmacology of 2\u02b9,3\u02b9-dideoxy-2\u02b9,3\u02b9-didehydrothymidine, a nucleoside analog active against human immunodeficiency virus",
        "Effects of drugs on 2\u02b9,3\u02b9-dideoxy-2\u02b9,3\u02b9-didehydrothymidine phosphorylation in vitro",
        "Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation",
        "Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study",
        "Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake",
        "Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients",
        "Influence of ABCC2 and ABCC4 polymorphisms on tenofovir plasma concentrations in Thai HIV-infected patients",
        "ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen",
        "Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines",
        "Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy",
        "Two\u2019s a company, three\u2019s a crowd: a review of initiating or switching to a two-drug antiretroviral regimen in treatment-naive and treatment-experienced patients living with HIV-1",
        "Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials",
        "Perspectives on the barrier to resistance for dolutegravir + lamivudine, a two-drug antiretroviral therapy for HIV-1 Infection",
        "Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials",
        "Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353",
        "Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL)",
        "Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial",
        "Bioequivalence and food effect assessment of 2 fixed-dose combination formulations of dolutegravir and lamivudine",
        "A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients",
        "Changes in body mass index and atherosclerotic disease risk score after switching from tenofovir disoproxil fumarate to tenofovir alafenamide",
        "Dual antiretroviral therapy for the treatment of HIV-1 infection"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60016965",
            "affilname": "The HIV Netherlands Australia Thailand Research Collaboration",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60016965",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": []
}